• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Neu: ceramic.implant by vitaclinical

, Medizintechnik, Vita Zahnfabrik H. Rauter GmbH & Co. KG

VITA Zahnfabrik ist unangefochtener Experte auf dem Gebiet moderner Dentalkeramiken und seit jeher Anbieter von Gesamtlösungen mit biologisch-ästhetischem...

4. DGET-Jahrestagung in Hamburg: Endodontologen trafen sich, auf JADENT und auf Dentalmikroskope

, Medizintechnik, JADENT microscopes and more e.K.

Gefühlt interessierten sich nahezu alle Teilnehmer für die Dentalmikroskope, die Lupenbrillen und das innovative 3D System MoraVision am JADENT-Stand....

Functionalizing and reducing germ counts on PEEK implants directly before insertion

, Medizintechnik, relyon plasma GmbH

In the manufacture of implants, for example for dental applications, more and more producers have started using the high-performance plastic...

Disclaimer